Acrotech BioPharma
Founded in 2018, Acrotech Biopharma is a pharmaceutical commercial platform focused on developing, acquiring, and commercializing proprietary medications with initial emphasis on oncology and dermatology. The company builds commercial infrastructure, manages medical affairs and medical information, operates pharmacovigilance channels, and pursues licensing and partnership arrangements to advance clinical-stage and market-ready assets into the U.S. market.
Industries
Nr. of Employees
medium (51-250)
Acrotech BioPharma
Hightstown, New Jersey, United States
Patents
Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
US-12527750-B2
View DetailsPharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
US-12016830-B2
View Details
Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
US-12527750-B2
View DetailsPharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
US-12016830-B2
View DetailsProducts
Beleodaq (belinostat)
Approved oncology injectable product with prescribing information provided on the company site.
Ryzneuta (efbemalenograstim alfa-vuxw)
Supportive therapy for chemotherapy-induced neutropenia with prescribing information and medical information channels.
Folotyn (pralatrexate)
Oncology product with provided prescribing information.
Zevalin (ibritumomab tiuxetan)
Radiolabeled oncology therapy with prescribing information referenced on the site.
Evomela (melphalan)
Oncology injectable product with prescribing information available.
Khapzory (levoleucovorin)
Supportive oncology product with prescribing information.
Beleodaq (belinostat)
Approved oncology injectable product with prescribing information provided on the company site.
Ryzneuta (efbemalenograstim alfa-vuxw)
Supportive therapy for chemotherapy-induced neutropenia with prescribing information and medical information channels.
Folotyn (pralatrexate)
Oncology product with provided prescribing information.
Zevalin (ibritumomab tiuxetan)
Radiolabeled oncology therapy with prescribing information referenced on the site.
Evomela (melphalan)
Oncology injectable product with prescribing information available.
Khapzory (levoleucovorin)
Supportive oncology product with prescribing information.
Services
Structuring licensing and partnership deals for clinical-stage and commercial assets, offering financing and commercial infrastructure to partners.
HCP-facing medical information support via phone and email for prescribing and safety inquiries.
Dedicated safety reporting channels and adverse event management processes.
Patient access resources and portals to support access to therapies and patient assistance operations.
Structuring licensing and partnership deals for clinical-stage and commercial assets, offering financing and commercial infrastructure to partners.
HCP-facing medical information support via phone and email for prescribing and safety inquiries.
Dedicated safety reporting channels and adverse event management processes.
Patient access resources and portals to support access to therapies and patient assistance operations.
Expertise Areas
- Oncology — hematologic malignancies and select rare solid tumors
- Dermatology — immunology-related skin conditions
- Product commercialization and launch management
- Business development and licensing
Key Technologies
- Pharmacovigilance reporting systems
- Medical information call-center and email support platforms
- Clinical program management systems
- Regulatory submission and labeling management processes
News & Updates
Scientific/medical conference participation listed on the events calendar.
Scientific/medical conference participation listed on the events calendar.
Press material referencing FDA approval and commercialization arrangements for a supportive oncology therapy in the U.S.
Signed agreement to acquire seven hematology and oncology drugs and associated U.S. commercial infrastructure (transaction up to $300M including milestones).
Scientific/medical conference participation listed on the events calendar.
Scientific/medical conference participation listed on the events calendar.
Press material referencing FDA approval and commercialization arrangements for a supportive oncology therapy in the U.S.
Signed agreement to acquire seven hematology and oncology drugs and associated U.S. commercial infrastructure (transaction up to $300M including milestones).